( er of resistant clones. According to ...)Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published,Health

According to Professor Lundgren, "It is widely known that melanoma cells often develop resistance to recombinant alpha interferon therapies. We observed dramatically different outcomes when comparing Multiferon(R) against Intron(R) A in human melanoma cell lines in vitro, with Multiferon(R) clearly suppressing resistance development far more efficiently than Intron(R) A after four weeks of treatment. One possibility is that multiple subtypes of alpha interferon in Multiferon(R) are working synergistically to eradicate resistant cell clones. If Multiferon(R) is indeed suppressing the development of resistant melanoma clones, this effect may have played a role in improving overall survival in melanoma patients in Viragen's previously reported Phase II/III melanoma trial, published last year in Acta Oncologica."

In February 2006, Multiferon(R) was approved in Sweden for the first-line adjuvant treatment of high-risk malignant melanoma. Viragen is preparing to proceed with a European Union (EU) regulatory process for Multiferon(R), through a registration pathway called the Mutual Recognition Procedure (MRP). This procedure allows a single registration dossier to be filed for approval among a targeted group of EU countries via one application and review process.

* Intron(R) A is registered trademark of Schering-Plough Corporation

About Malignant Melanoma:

Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. The American Cancer Society estimates that in 2006 there were 62,190 new cases of melanoma in the United States and about 7,910 people died of this disease.

About Multiferon(R):

Alpha interferon is produced by the human immune system and helps improve the body's natural resistance to disease.

Multiferon(R) differs from single-subtype recombinant alpha in
'"/>